CTC enumeration has been a valid staging and prognostic biomarker for breast cancer but lack of significance in predicting the survival of HER2+ patients during anti-HER2 treatment (Giordano et al., 2012; Amin et al., 2017; Heitzer et al., 2019). Here, ERBB2 is linked to breast carcinoma.